Wockhardt Limited
WOCKPHARMA
Classificação em ações
#4523
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Preço da ação
$20.95
Valor de mercado
$3.40B
Variação (1 dia)
-0.44%
Variação (1 ano)
34.31%
País
IN
Negociar Wockhardt Limited (WOCKPHARMA)
Categoria
Healthcare
Lucros da Wockhardt Limited (WOCKPHARMA)
Lucros em Jun 2026 TTM: $51.10M
De acordo com os últimos relatórios financeiros da Wockhardt Limited, os ganhos atuais da empresa são de $51.10M. Em 2024, a empresa teve ganhos de $-50.37M, um aumento em relação a aos ganhos de 2023, que foram de $-75.93M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Wockhardt Limited de 2004 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $51.10M | -2,831.29% |
| 2025 | $-1.87M | -96.29% |
| 2024 | $-50.37M | -33.66% |
| 2023 | $-75.93M | 40.24% |
| 2022 | $-54.14M | -30.22% |
| 2021 | $-77.59M | 70.90% |
| 2020 | $-45.40M | -29.40% |
| 2019 | $-64.31M | -34.69% |
| 2018 | $-98.47M | 158.38% |
| 2017 | $-38.11M | -187.03% |
| 2016 | $43.79M | -52.51% |
| 2015 | $92.20M | -37.95% |
| 2014 | $148.59M | -56.05% |
| 2013 | $338.11M | 197.28% |
| 2012 | $113.73M | 385.74% |
| 2011 | $23.41M | -110.67% |
| 2010 | $-219.46M | 324.20% |
| 2008 | $-51.73M | -142.94% |
| 2007 | $120.48M | 81.57% |
| 2006 | $66.36M | 1.54% |
| 2005 | $65.35M | 13.32% |
| 2004 | $57.67M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $1.35B | 2,541.82% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -48.39% |
US
|
